SecuGen and Valid Technologies Collaborate to Bring Biometrics to IBM Enterprise Computing Environments
Tue, 18 Aug 2009, 08:00:45 EDT — Edited by Carly Zander
SANTA CLARA, Calif. (SEND2PRESS NEWSWIRE) -- SecuGen and Valid Technologies are pleased to announce a technology and marketing partnership to deliver strong user authentication solutions to IBM enterprise computing customers. As a result of this partnership, the Valid Technologies VSSA® Strong User Authentication solution will include support for SecuGen biometric matching technologies and the SecuGen Hamster family of biometric fingerprint readers.

M2SYS Biometric Software Solution Selected by GHG Corporation
Tue, 04 Aug 2009, 07:59:11 EDT — Edited by Carly Zander
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric technology research and development firm, announced today that GHG Corporation, an innovative time tracking software provider, has chosen to provide their customers with M2SYS' Bio-SnapON™ biometric software solution.

ACS Technologies Selects M2SYS for Innovative Biometric Software
Tue, 07 Jul 2009, 08:29:19 EDT — Edited by Carly Zander
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric technology research and development firm, announced today that it has finalized an agreement with ACS Technologies, the leading provider of information management solutions to nearly 50,000 churches, schools, and other faith-based organizations.

SecuGen Offers Free SDKs for Fingerprint Software Development
Thu, 25 Jun 2009, 15:29:19 EDT — Edited by Debra Tone
SANTA CLARA, Calif. (SEND2PRESS NEWSWIRE) -- SecuGen, the world's leading optical fingerprint device vendor, is pleased to announce that it is now providing all of its industry leading fingerprint template extraction and matching SDKs free of charge. Included in SecuGen's wide selection of Software Developer Kits are SDKs for Windows Vista, Windows CE, Linux, Solaris and more.

Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
Mon, 22 Jun 2009, 12:45:51 EDT — Edited by Carly Zander
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body.

Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Wed, 17 Jun 2009, 06:00:17 EDT — Edited by Debra Tone
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.

The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
Tue, 09 Jun 2009, 07:59:24 EDT — Edited by Carly Zander
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
Mon, 18 May 2009, 12:45:19 EDT — Edited by Carly Zander
SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.

iPulse Selects SecuGen's SDA04M Fingerprint Module for the iPB6 Access Control Unit
Mon, 11 May 2009, 08:01:59 EDT — Edited by Carly Zander
SANTA CLARA, Calif., May 11 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce that iPulse Systems, South Africa's leading biometrics company, has selected SecuGen's SDA04M fingerprint module as the core fingerprint engine for the iPB6, the next generation in biometric readers.

M2SYS Fingerprint Biometrics System Selected by VinDec Enterprise Solutions to Verify Blood Donors
Thu, 16 Apr 2009, 12:40:38 EST — Edited by Carly Zander
ATLANTA, Ga., April 16 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that VinDec Enterprise Solutions has integrated M2SYS' Bio-Plugin(TM) fingerprint software and M2-EasyScan(TM) fingerprint reader into its blood donor management system. The biometric identification system will be initially used by the Allahabad Medical Association (AMA) Blood Bank.

Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
Thu, 12 Feb 2009, 15:58:45 EST — Edited by Carly Zander
SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body.

New Sales Personality Report Uses a Form of Body Language to Help Sales Teams Close More Business
Tue, 10 Feb 2009, 12:47:33 EST — Edited by Carly Zander
TEMECULA, Calif., Feb. 10 (SEND2PRESS NEWSWIRE) -- Written Inc. today released Salesperson Insight, a new type of sales personality report that teaches salespeople how their traits are impacting their sales, what they're communicating to their prospect through their body language and what they can do specifically to change and improve.

While Most Companies and Industries Struggled in 2008, LifeModeler, Inc. Used Unique Products to Post Aggressive Business Gains in All Areas
Wed, 04 Feb 2009, 08:29:08 EST — Edited by Carly Zander
SAN CLEMENTE, Calif., Feb. 4 (SEND2PRESS NEWSWIRE) -- To say that LifeModeler, Inc. (LMI) bucked the prevailing trend and posted a series of successes in 2008 that are providing a platform for even greater accomplishments this year, wouldn't quite be telling the whole story. This past year will actually be considered the most formative for the young company, as it literally expanded its presence in every category-from revenue and customer growth, to staff enhancement, to university teaching programs, and even to helping put men on Mars.

Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer
Mon, 19 Jan 2009, 20:32:23 EST — Edited by Carly Zander
SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.

SecuGen SDA04(TM) and SDA04M(TM) OEM Fingerprint Sensors Raise the Bar on Biometric Access Control
Wed, 14 Jan 2009, 16:53:10 EST — Edited by Carly Zander
SANTA CLARA, Calif., Jan. 14 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce the immediate availability of two new ultra high capacity OEM fingerprint sensors, the SDA04M(TM) and the SDA04(TM). The SDA04M is intended for commercial biometrics applications, and the SDA04 is intended for government and commercial applications where FIPS 201/PIV compliance is required.

RPGSi Selects M2SYS Fingerprint Biometrics Software for Revolutionary Patient Identification System
Tue, 13 Jan 2009, 11:36:40 EST — Edited by Carly Zander
ATLANTA, Ga., Jan. 13 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that RPGSi Business Solutions, a provider of effective and high quality technology and information systems to Latin America, has integrated M2SYS' Bio-Plugin(TM) Appserver fingerprint software into its HealthGest(TM) healthcare software. RPGSi will be distributing the fingerprint recognition solution with M2SYS' M2-S(TM) optical fingerprint reader.

Sun Microsystems and SecuGen Collaborate to Bring Fingerprint Biometrics to Sun Solaris, SunRay, and Sun Identity Management Solutions
Thu, 08 Jan 2009, 11:49:43 EST — Edited by Carly Zander
SANTA CLARA, Calif., Jan. 8 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce that its Hamster(TM) Plus and Hamster(TM) IV fingerprint biometric readers are now compatible with Sun Solaris, Sun Ray, and Sun's Identity Management Solutions. SecuGen's engineering and Sun's ISV engineering team worked closely together to provide a seamless integration of their products.

Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
Tue, 16 Dec 2008, 11:36:13 EST — Edited by Carly Zander
SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic targeting.

InvoTech Selects M2SYS Technology for Leading-Edge Fingerprint Software Solution
Mon, 24 Nov 2008, 13:56:26 EST — Edited by Carly Zander
ATLANTA, Ga., Nov. 24 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that InvoTech Systems Inc., the leading provider of 'back-of the-house' inventory tracking systems for the hospitality industry, has chosen M2SYS Technology to provide its customers with M2SYS' Bio-SnapON(TM) enterprise-ready fingerprint recognition software and with M2SYS' M2-EasyScan(TM) optical fingerprint reader.

Biometric Technologies Inc. Selects SecuGen's Hamster(TM) IV Fingerprint Reader to Reduce Phantom Billing
Mon, 03 Nov 2008, 16:53:04 EST — Edited by Carly Zander
SANTA CLARA, Calif., Nov. 3 (SEND2PRESS NEWSWIRE) -- SecuGen Corporation is pleased to announce that Biometric Technologies, Inc. has integrated the SecuGen Hamster(TM) IV into BIOCLAIM(R), their flagship software product. BIOCLAIM is the only medical billing solution that provides biometric confirmation that a patient was actually present to receive healthcare services.

Targeting Metastatic Cancer from the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
Mon, 06 Oct 2008, 12:14:50 EDT — Edited by Carly Zander
SAN MARINO, Calif., Oct. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled 'Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ,' was published in the October issue of the International Journal of Oncology.

FBI Certifies SecuGen's SDA04 OEM Fingerprint Sensor Module as FIPS 201/PIV Compliant
Tue, 23 Sep 2008, 14:55:24 EDT — Edited by Carly Zander
SANTA CLARA, Calif., Sept. 23 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce that the SDA04, an advanced single finger capture device, has been certified by the FBI as compliant with the U.S. Government's FIPS 201/PIV requirements. FIPS 201 places stringent requirements on the image quality of fingerprint devices as established by the FBI's Image Quality Specifications. The SDA04 is an OEM module consisting of a fingerprint sensor and processing board that can store and perform fast 1:N search on up to 10,000 users.

LifeModeler, Inc. Provides $400,000 Grant to Inmotion Musculoskeletal Institute
Thu, 18 Sep 2008, 13:07:10 EDT — Edited by Carly Zander
SAN CLEMENTE, Calif., Sept. 18 (SEND2PRESS NEWSWIRE) -- A software grant that could lead to orthopedic surgeons being able to immediately gauge the effectiveness of implanted joints has been announced by LifeModeler, Inc. The company, a leading global provider of biomechanical human body simulation tools and services, will provide $400,000 of software and services to InMotion Musculoskeletal Institute and the University of Memphis, Memphis, Tenn.

SecuGen's SDA03M(TM) Fingerprint Sensor Module Redefines Access Control for OEMs
Mon, 08 Sep 2008, 18:42:33 EDT — Edited by Carly Zander
SANTA CLARA, Calif., Sept. 8 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce the immediate availability of its newest OEM fingerprint sensor module, the SDA03M. The SDA03M features a large storage capacity of 3,000 users and will perform a fast one-to-many identification in an average of 0.2 seconds at full capacity. The SDA03M also has an impressive 460,800 bps data transfer rate. In the fourth quarter of this year a second version of firmware will be made available with a capacity of 32,000 users for one-to-one matching only.

SecuGen Broadens Platform Support and Adds New NIST MINEX SDKs to The SecuGen SDK Collection, Release 11
Mon, 25 Aug 2008, 15:38:22 EDT — Edited by Carly Zander
SANTA CLARA, Calif. (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce the immediate availability of the SecuGen SDK Collection, Release 11. This new release adds Software Developer Kits that reflect SecuGen's commitment to continuing its efforts to provide Independent Software Vendor (ISV) partners with the broadest platform support in the biometrics industry.

M2SYS Technology Selected by TimeForge to Integrate Fingerprint Software
Tue, 29 Jul 2008, 13:50:36 EDT — Edited by Carly Zander
ATLANTA, Ga., July 29 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that it has reached an agreement with TimeForge, a provider of web-based scheduling and time and attendance solutions to the hospitality industry. Through the terms of this agreement, TimeForge will be providing its customers with a seamless, integrated biometric identification system consisting of M2SYS fingerprint software and fingerprint readers.

M2SYS Technology Selected by ZOLL Data Systems to Integrate Fingerprint Software
Thu, 10 Jul 2008, 11:18:08 EDT — Edited by Carly Zander
ATLANTA, Ga., July 10 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that it has finalized a partnership agreement with ZOLL Data Systems(R), an industry leader in the development of EMS and fire department management software, to provide fingerprint software and hardware to ZOLL Data Systems' customers.

SecuGen Hamster IV, FIPS 201/PIV Fingerprint Reader, Now Listed on AC Technology's GSA Schedule
Tue, 27 May 2008, 12:24:20 EDT — Edited by Carly Zander
SANTA CLARA, Calif., May 27 (SEND2PRESS NEWSWIRE) -- SecuGen Corporation is pleased to announce that it has chosen AC Technology, Inc. as its primary GSA holder for the SecuGen Hamster(TM) IV and SecuDesktop(R) Pro line of FIPS 201 certified fingerprint scanners and software. The two companies have been working together on several biometric projects within the Department of Defense.

M2SYS Fingerprint Software Integrated with Medical Marijuana Dispensary Management Solution
Wed, 21 May 2008, 16:20:23 EDT — Edited by Carly Zander
ATLANTA, Ga., May 21 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that it has finalized an agreement with IMCL (Innovative Marijuana Caregiver Logistics), a leading provider of inventory and patient management solutions to the medical marijuana dispensary industry. Through this agreement, IMCL has exclusive rights to integrate the Bio-Plugin(TM) fingerprint solution with its CA-MMPR patient registry product.

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
Mon, 19 May 2008, 07:10:36 GMT — Edited by Carly Zander
SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks.

Prevent Identity Theft - Biometric Signature ID and QBOS Partner to Strengthen Online Identity Authentication
Tue, 13 May 2008, 08:35:23 GMT — Edited by Carly Zander
DALLAS, Texas, May 13 (SEND2PRESS NEWSWIRE) -- Biometric Signature ID (BSI) and Quick Business Operating Systems (QBOS) today announced a strategic alliance that will enable BSI's dynamic biometric authentication and verification solutions to seamlessly operate within QBOS's Business Process Automation Suite of products.

New and Improved SecuGen Hamster(TM) Plus Fingerprint Reader with Smart Capture(TM) is Now Faster, Better, Cheaper
Wed, 02 Apr 2008, 08:30:20 GMT — Edited by Carly Zander
SANTA CLARA, Calif., April 2 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce the immediate availability of an improved version of the Hamster Plus fingerprint reader. This newly upgraded device captures fingerprint images much faster than previously. In addition, the Hamster Plus now makes the Smart Capture feature available. Smart Capture automatically adjusts the sensor brightness to capture fingerprints from dry and moist fingers.

DAXKO Partners with M2SYS to Offer Fingerprint Software Solution to YMCAs
Tue, 25 Mar 2008, 12:20:45 GMT — Edited by Carly Zander
ATLANTA, Ga., March 25 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric technology research and development firm, announced today that it has finalized an agreement with DAXKO, a leading provider of operations software and services to the YMCA market. The agreement will benefit YMCAs and their members by speeding the flow of critical information and increasing the efficiency of operations.

Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him
Tue, 25 Mar 2008, 02:00:11 GMT — Edited by Carly Zander
FRESNO, Calif., March 25 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company's Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for the new east coast office.

Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
Tue, 25 Mar 2008, 01:05:29 GMT — Edited by Carly Zander
SAN MARINO, Calif., March 25 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G.

Breakthrough in Handwriting Analysis Leads to Revolutionary Hiring Tool
Wed, 19 Mar 2008, 15:18:12 GMT — Edited by Liisa Sullivan
TEMECULA, Calif., March 19 (SEND2PRESS NEWSWIRE) -- Written Inc. has developed a breakthrough technology which has led to the first significant improvement to the 150-year-old science of handwriting analysis. This week, the company released the latest version of their personality assessment tool, Candidate Insight(TM).

Club Sentry Selects SecuGen(R) Hamster(TM) Fingerprint Readers for Use with Biometric Check-in Software
Mon, 10 Mar 2008, 12:06:15 GMT — Edited by Carly Zander
SANTA CLARA, Calif., March 10 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce that Club Sentry, Inc. has chosen SecuGen's Hamster fingerprint readers for integration with Club Sentry's club management software. The Hamster readers will be used to scan fingerprints of members when they check-in and check-out through Club Sentry's Biometric ID software module.

M2SYS Introduces Revolutionary Biometric Artificial Intelligence Technology to Significantly Reduce Fingerprint Software False Reject Rates
Wed, 27 Feb 2008, 11:35:18 GMT — Edited by Carly Zander
ATLANTA, Ga., Feb. 27 (SEND2PRESS NEWSWIRE) -- M2SYS, an award-winning biometric technology research and development firm, announced today the release of their newest fingerprint biometrics innovation: Bio-AI(TM). This exciting new artificial intelligence enhancement uses a unique 'dynamic profiling' technique to learn about a person's fingerprints over time.

Biometric Signature ID CEO Jeff Maynard to Speak on Identity Fraud Reduction Using Dynamic Biometrics at InnoTech San Antonio
Thu, 21 Feb 2008, 09:45:23 GMT — Edited by Carly Zander
DALLAS, Texas - Feb. 21 (SEND2PRESS NEWSWIRE) -- Biometric Signature ID (BSI) announces that its CEO, Jeff Maynard, will be a featured speaker at InnoTech, the Business & Technology Innovation Conference to take place at the Norris Convention Center in San Antonio, Texas. Mr. Maynard is scheduled to speak on Thursday March 6, 2007 at 8:30 a.m. on a very popular topic entitled 'Biometric Signatures for Identity Authentication and Reduction in Identity Fraud.'

SecuGen Fingerprint Readers Now Work with Tutis Biometric Logon Software to Authenticate Users to Active Directory
Wed, 06 Feb 2008, 15:15:18 GMT — Edited by Carly Zander
SANTA CLARA, Calif. - Feb. 6 (SEND2PRESS NEWSWIRE) -- SecuGen Corporation, a world leading fingerprint technology company, announced today that its well-known Hamster(TM) line of fingerprint readers is now available with Tutis Biometric Logon, an Active Directory compatible network authentication application.

SecuGen Fingerprint Technology Now Supported on WCC's Multi-Modal Fusion Platform
Mon, 04 Feb 2008, 08:45:06 GMT — Edited by Carly Zander
SANTA CLARA, Calif. - Feb. 4 (SEND2PRESS NEWSWIRE) -- SecuGen Corporation, a world leading fingerprint technology company, today announced its collaboration with WCC Smart Search & Match, a leading provider of high-performance search and match software. 'Our partnership with SecuGen brings together two key technologies to deliver on the promise of multi-modal fusion,' said Peter Went, CEO of WCC.

Biometric Signature ID Announces Teaming Agreement with Zolon Tech for U.S. Dept of State
Wed, 23 Jan 2008, 15:12:30 GMT — Edited by Carly Zander
DALLAS, Texas - Jan. 23 (SEND2PRESS NEWSWIRE) -- Biometric Signature ID (BSI) CEO Jeff Maynard announces it has signed a teaming agreement to become a member of a team led by Zolon Tech, Inc. of Sterling, Virginia that was recently awarded a prime contract for the U.S. Department of State's Hybrid Information Technology Support Services (HITSS) program. Through the HITSS contract, this team will support the State Department's mission at headquarters and field offices throughout the United States and internationally.

LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information
Tue, 22 Jan 2008, 00:30:10 GMT — Edited by Carly Zander
ATLANTA, Ga. - Jan. 22 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric fingerprint technology firm, announced today that LOGICARE Corporation has enhanced its OnRecord(TM) healthcare solution for emergency departments and patient educators by integrating M2SYS' Bio-Plugin(TM) fingerprint software. The biometric module is now available to LOGICARE's growing customer base for OnRecord(TM) solutions throughout the United States.

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Mon, 17 Dec 2007, 14:46:32 GMT — Edited by Carly Zander
SAN MARINO, Calif. - Dec. 17 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers. Developed as a tumor-targeted anticancer agent, that actively seeks out and destroys metastatic cancers, Rexin-G exhibits unprecedented single-agent efficacy.

Bromba Biometrics' BioIDENTICA(R) SDK Toolkit Now Supports SecuGen(R) Hamster(TM) Line of Fingerprint Readers
Thu, 13 Dec 2007, 14:46:49 GMT — Edited by Debra Tone
SANTA CLARA, Calif. - Dec. 13 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce that Bromba Biometrics BioIDENTICA SDK is now compatible with SecuGen Hamster III, Hamster Plus and Hamster IV fingerprint readers. The BioIDENTICA SDK allows a simple integration of fingerprint technology into any existing or new software application that can benefit from biometric authentication.

SecuGen Fingerprint Readers Now Compatible with realtime's bioLock Software for Authentication of SAP Applications, Transactions and Data
Wed, 12 Dec 2007, 12:25:17 GMT — Edited by Debra Tone
SANTA CLARA, Calif. - Dec. 12 (SEND2PRESS NEWSWIRE) -- SecuGen is pleased to announce that realtime has integrated SecuGen fingerprint readers with realtime's bioLock Software to provide biometric authentication and fraud mitigation for SAP applications. To date, bioLock is the only certified technology available for ERP market leader, SAP, that offers biometric access and function control.

ZK Software Selects SecuGen Sensor for S900 Access Control and Time and Attendance Terminal
Tue, 11 Dec 2007, 12:21:29 GMT — Edited by Carly Zander
SANTA CLARA, Calif. - Dec. 11 (SEND2PRESS NEWSWIRE) -- SecuGen, a world-leading provider of fingerprint recognition technology, is pleased to announce that ZK Software has selected SecuGen's FDU02 fingerprint sensor for integration with its newly released S900 access control and time and attendance terminal.

Software Techniques Inc. Selects M2SYS Fingerprint Software to Meet Continuous Growth and Demand for Desktop Biometric Time and Attendance Solutions
Tue, 27 Nov 2007, 07:30:18 GMT — Edited by Carly Zander
ATLANTA, Ga. - Nov. 27 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric fingerprint technology firm, announced today that Software Techniques Inc. has enhanced their TimeKRON PC-based time and attendance software by integrating M2SYS' Bio-SnapON(TM) solution.

Bioscrypt Integrates SecuGen's Fingerprint Sensor into the V-Station (Optical) Reader
Mon, 19 Nov 2007, 14:49:16 GMT — Edited by Carly Zander
SANTA CLARA, Calif. - Nov. 19 (SEND2PRESS NEWSWIRE) -- SecuGen is proud to announce that Bioscrypt Inc. (TSX: BYT), a leading provider of identity and access management solutions, has chosen to integrate SecuGen's fingerprint sensor into their V-Station (Optical) reader.

Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston
Thu, 18 Oct 2007, 22:13:00 GMT — Edited by Carly Zander
SAN MARINO, Calif. and BOSTON, Mass. - Oct. 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on 'The Advent of Pathotropic Medicine for Cancer' at the Global Pharma R&D Summit 2007 to be held in Boston.

Biometric Signature ID Launches its Biometric Signature and Gesture Technology Called BioSig-ID(TM) Authentication Products at 2007 InnoTech Austin
Tue, 02 Oct 2007, 23:43:00 GMT — Edited by Debra Tone
DALLAS, Texas - Oct. 2 (SEND2PRESS NEWSWIRE) -- Biometric Signature ID (BSI) announces that CEO, Jeffrey Maynard, will be a speaker at 2007 InnoTech Austin, the Business & Technology Innovation Conference & Expo to take place at the Austin Convention Center. Mr. Maynard will speak Thursday, October 11.

M2SYS Technology Partners with TeraCorp Enterprises to Provide Added Security within Check Cashing Solution
Thu, 27 Sep 2007, 18:17:00 GMT — Edited by Debra Tone
ATLANTA, Ga. - Sept. 27 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a leading biometric technology research and development firm, announced today its partnership with TeraCorp Enterprises, a leading provider of check cashing and verification solutions, to integrate the M2SYS Bio-Plugin(TM) fingerprint solution into TeraCash, a cutting-edge check cashing system.

M2SYS Partners with Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries through Innovative Biometrics Solution
Tue, 28 Aug 2007, 14:49:00 GMT — Edited by Debra Tone
ATLANTA, Ga. - Aug. 28 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric technology research and development firm, announced today that they have partnered with Gnosis Medical Services to provide a biometric fingerprint solution for patient identification in developing countries.

SecuGen Partners with M2SYS' Award Winning Bio-Plugin(TM) Solution
Tue, 21 Aug 2007, 17:21:00 GMT — Edited by Carly Zander
SANTA CLARA, Calif. - Aug. 21 (SEND2PRESS NEWSWIRE) -- SecuGen, a world leading optical fingerprint recognition technology company, announced today its partnership with M2SYS Technology, a biometric technology research and development firm, to support their award winning Bio-Plugin(TM) software that allows software developers to rapidly integrate a complete, server-based, turn-key fingerprint software system with hardly any development effort.

M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
Tue, 14 Aug 2007, 14:15:00 GMT — Edited by Carly Zander
ATLANTA, Ga. - Aug. 14 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a biometric technology research and development firm, announced today its partnership with SecuGen Corporation to support their revolutionary fingerprint reader, the Hamster Plus. The Hamster Plus fingerprint reader features innovative Auto-On technology that automatically checks for the presence of a finger.

Stromberg Selects M2SYS for Seamless Biometric Technology Interface to Enterprise Time and Attendance Solution
Tue, 31 Jul 2007, 13:45:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - July 31 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an award-winning biometric fingerprint technology firm, announced today that Stromberg, a subsidiary of Paychex, Inc. (NASDAQ:PAYX), and a leading provider of time and attendance solutions for mid- to large-sized businesses, has integrated M2SYS' Bio-SnapON(TM) solution into their Web-enabled time and attendance software. The addition of a fingerprinting module to the time-clock solution will increase employee accountability while enabling employers to reduce time and money spent on employee management.

California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System
Tue, 10 Jul 2007, 14:00:00 GMT — Edited by Chris Simmons
SAN MARINO, Calif. - July 10 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers.

NUTRIKIDS Selects M2SYS Fingerprint Software to Instantly Meet Accumulating Demand for Fingerprint Software in School Lunch Lines
Mon, 02 Jul 2007, 16:00:00 GMT — Edited by Debra Tone
ATLANTA, Ga. - July 2 (SEND2PRESS NEWSWIRE) -- M2SYS, an award-winning biometric technology research and development firm announced today that LunchByte Systems, Inc., home of the NUTRIKIDS brand of foodservice management solutions, has integrated M2SYS' unique Bio-SnapON(TM) solution into their lunchline POS system; instantly increasing the security and efficiency of their application.

Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation
Mon, 18 Jun 2007, 23:36:00 GMT — Edited by Chris Simmons
PASADENA, Calif. - June 18 (SEND2PRESS NEWSWIRE) -- Osmetech plc (LSE, AIM; OMH) today announced that it has granted a non-exclusive research license to Waltham, Massachusetts, US-based Minerva Biotechnologies Corporation ('Minerva') for use of Osmetech's self-assembling monolayer (SAM) technology in conjunction with Minerva's proprietary nanoparticle technology.

Mark Whitacre, Ph.D. Joins Management Team at Cypress Systems, Inc.
Wed, 13 Jun 2007, 14:15:00 GMT — Edited by Chris Simmons
FRESNO, Calif. - June 13 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has hired Mark Whitacre, Ph.D. Dr. Whitacre joined the executive management team effective January 1, 2007 as COO & President, Technology and Business Development, following the opening of a new office in Pensacola, Florida in December, 2006.

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
Mon, 04 Jun 2007, 17:38:00 GMT — Edited by Carly Zander
SAN MARINO, Calif. - June 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour - published in the June issue of the International Journal of Oncology, Vol.30, pp. 1297-1307 - documents the histologic features of tumor destruction observed in chemo-resistant cancers.

Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
Mon, 04 Jun 2007, 15:53:00 GMT — Edited by Chris Simmons
SAN MARINO, Calif. - June 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.

Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences
Tue, 15 May 2007, 14:00:00 GMT — Edited by Chris Simmons
SAN MARINO, Calif. - May 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 at 11:15 am, Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology embodied in its lead product, Rexin-G.

M2SYS Accepts Frost and Sullivan's Prestigious 2007 North American Biometrics Technology Innovation of the Year Award
Tue, 01 May 2007, 13:53:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - May 1 (SEND2PRESS NEWSWIRE) -- Frost & Sullivan presented M2SYS Technology with its 2007 North American Biometrics Technology Innovation of the Year Award at the 2007 North American Excellence in Industrial Technologies Awards Banquet. M2SYS honored for its innovative developments and outstanding performance in the biometrics industry.

M2SYS Fingerprint Software Eliminates Privacy Concerns and Establishes Success in UK School System through Powerful Biometric Identification Technology
Wed, 21 Mar 2007, 16:00:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - Mar. 21 (SEND2PRESS NEWSWIRE) -- M2SYS Technology announced today the completion of an ongoing case study with point of sale solutions partner, LCR Limited. In early 2006, LCR integrated M2SYS' flagship fingerprint software, Bio-Plugin(TM), into their QuickDine(TM) school lunchroom management software to provide an alternative to magnetic swipe-cards that were previously used to identify students purchasing lunch.

M2SYS Delivers Rapid Fingerprint Integration Technology to Support Successful Deployment of Biometrically Controlled Nigerian Voting Project
Mon, 19 Feb 2007, 13:00:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - Feb. 19 (SEND2PRESS NEWSWIRE) -- M2SYS Technology announced today that it was selected late in 2006 by a leading Nigerian IT products provider to deliver fingerprint scanners and software for the secure national voting project. After the original local vendor selected for the project faced delays in meeting its timeline for the fulfillment of a portion of needed IT units, Nigerian government officials sought out the help of another company, who turned to M2SYS for assistance.

ID Solutions Announces Order and Delivery of AFIS Enrollment Licenses for the Initial Transportation Worker Identification Credential
Mon, 29 Jan 2007, 15:27:00 GMT — Edited by Chris Simmons
ORLANDO, Fla. - Jan. 29 (SEND2PRESS NEWSWIRE) -- Orlando, Florida-based ID Solutions (IDS) today reported receipt of a purchase order from the Transportation Security Agency (DHS-TSA) for IDS biometric matching licenses for use in the Transportation Worker Identity Credential (TWIC) program. The IDS AFIS technology supports key security functionality within the TWIC program and has been recognized for its combination of top-rated accuracy and value-for-money by governments around the world.

Schoolhouse Software Selects M2SYS Fingerprint Software to Provide Integrated Biometric Identification System for School Lunch Line POS
Mon, 08 Jan 2007, 16:27:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - Jan. 8 (SEND2PRESS NEWSWIRE) -- M2SYS Technology announced today that it has formed a strategic partnership with Schoolhouse Software, a leading provider of K-12 lunch line management systems. This partnership will benefit school customers by enabling Schoolhouse to integrate M2SYS' market revolutionizing fingerprint software technology, Bio-Plugin(TM), within their Touch-n-Serv(TM) K-12 school lunch line POS solution.

Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G(TM) as Treatment for Diverse Metastatic Cancers
Wed, 06 Dec 2006, 13:45:00 GMT — Edited by Chris Simmons
SAN MARINO, Calif. and TOKYO, Japan - Dec. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006.

M2SYS Fingerprint Technology to be Integrated into Kodak Global Practice Management Software
Mon, 04 Dec 2006, 17:18:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - Dec. 4, 2006 (SEND2PRESS NEWSWIRE) -- M2SYS Technology announced today it has formed a relationship with Kodak's Dental Systems Group to integrate M2SYS' patent-pending fingerprint software into the KODAK ORTHOTRAC Practice Management Software. As a result, Kodak's customers will be able to secure sensitive patient information and comply with HIPAA requirements, while improving productivity and user experience by eliminating the time, hassle, and headache associated with password management.

Rexin-G(TM), The World's First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
Mon, 06 Nov 2006, 13:36:00 GMT — Edited by Chris Simmons
SAN MARINO, Calif. and MANILA, Philippines - Nov. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.

PCS Revenue Control Systems Selects M2SYS Fingerprint Software to Provide Powerful Biometric Identification Technology for School Cafeterias
Mon, 30 Oct 2006, 14:22:00 GMT — Edited by Chris Simmons
ATLANTA, Ga. - Oct. 30 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a biometric technology research and development company, announced today it has formed a partnership with PCS Revenue Control Systems, a leading provider of foodservice management technology. This partnership will benefit school districts by enabling PCS to integrate and distribute M2SYS' cutting edge fingerprint software technology, Bio-Plugin(TM), within their FASTRAK(TM) school meal software.

ACell Wins Again in Federal Appeals Court
Thu, 19 Oct 2006, 21:57:00 GMT — Edited by Carly Zander
JESSUP, Md. - Oct. 19 (SEND2PRESS NEWSWIRE) -- ACell, Inc., the owner of highly valued extracellular matrix (ECM) patents, along with co-defendants Dr. Stephen Badylak and Dr. Alan Spievack, today won another legal victory against Cook Biotech, Inc. (Cook) and Purdue Research Foundation (Purdue) when the Court of Appeals for the Federal Circuit denied Cook's and Purdue's Petition for Rehearing and Rehearing En Banc.

A Step Ahead of Resistance; Virco introduces an Improved Rapid Methodology to Establish New HIV-1 Resistance Profiles
Mon, 16 Oct 2006, 19:35:00 GMT — Edited by Carly Zander
MECHELEN, Belgium - Oct. 16 (SEND2PRESS NEWSWIRE) -- Responding to the need to make timely evaluations and decisions when treating treatment experienced HIV patients, Virco, a leader in drug resistance testing recently introduced an improved virco(R)TYPE HIV-1 test that rapidly determines the complex phenotypic resistance profiles for darunavir, tipranavir and other antiretroviral (ARV) drugs.

Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine
Wed, 11 Oct 2006, 16:18:00 GMT — Edited by Chris Simmons
SAN MARINO, Calif. - Oct. 11 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company's innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM).

Cyberonics CEO to Keynote 2006 Neurotech Leaders Forum
Thu, 14 Sep 2006, 18:43:00 GMT — Edited by Chris Simmons
SAN FRANCISCO, Calif. - Sept. 14 (SEND2PRESS NEWSWIRE) -- Robert P. 'Skip' Cummins, chairman and CEO of Cyberonics Inc., will keynote the 2006 Neurotech Leaders Forum, to be held September 28-29, 2006 at the Crowne Plaza San Francisco International Airport. The free-speaking neurotechnology industry pioneer will share some of his experiences dealing with regulatory, technical, and marketing issues during his tenure at Cyberonics. Several other neurotechnology leaders will contribute during the conference.

ACell, Inc. Wins Court Battle Initiated by Cook Biotech and Purdue
Mon, 21 Aug 2006, 18:29:00 GMT — Edited by Chris Simmons
JESSUP, MD - Aug. 21 (SEND2PRESS NEWSWIRE) -- ACell, Inc., the owner of highly valued extracellular matrix (ECM) patents, today won a resounding legal victory against Cook Biotech, Inc. (Cook) and Purdue Research Foundation (Purdue). The victory frees ACell to broadly promote the development, licensing and commercialization of its remarkable tissue graft bio-technology.

M2SYS Next Generation Plug-and-Play Fingerprint Identification Software Supports Any Matching Algorithm and Hardware Device
Thu, 17 Aug 2006, 17:10:00 GMT — Edited by Chris Simmons
ATLANTA, GA - Aug. 17 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a leading biometric technology research and development firm, today announced a new version release of Bio-Plugin(TM), a fully developed, server-based, enterprise fingerprint recognition system that can be rapidly deployed, in many cases with no additional development whatsoever. The patent-pending technology can utilize any vendor-independent fingerprint algorithm and supported hardware devices, offering unparalleled ease of adoption for software developers and end users.

Epeius Biotechnologies Initiates Tri-REX Vaccination Protocols for Breast Cancer
Wed, 05 Jul 2006, 16:04:00 GMT — Edited by Christopher L. Simmons
SAN MARINO, CA and MANILA, Philippines - July 5 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the opening of a Vaccine-assisted Phase I/II clinical trial for metastatic breast cancer that is refractory to conventional chemotherapy. The innovative protocol introduces Reximmune-C(TM), the second in a series of targeted biologic therapies designed to seek out, accumulate in, and destroy metastatic tumor nodules, while sparing normal cells and tissues.

Horizon Software Selects M2SYS Enterprise Fingerprint Software to Help Meet Burgeoning Demand for Fingerprint Technology in the School Lunch Line
Thu, 29 Jun 2006, 16:08:00 GMT — Edited by Christopher L. Simmons
ATLANTA, GA - June 29 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a biometric technology research and development company, announced today it has formed a partnership with Horizon Software, a leading provider of foodservice management technology. This partnership will benefit school customers by enabling Horizon to integrate and distribute M2SYS' cutting edge fingerprint software technology, Bio-Plugin(TM), within their FastLane(TM) school POS solution.

Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development
Tue, 20 Jun 2006, 15:15:00 GMT — Edited by Christopher L. Simmons
MALVERN, PA - June 20 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC's DiscoveryDot(TM) nanoliter screening platform.

Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer
Mon, 19 Jun 2006, 16:07:00 GMT — Edited by Christopher L. Simmons
SAN MARINO, CA - June 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.

Crescent Diagnostics Secures Venture Capital Financing Investment to Advance the Development of its Novel Bone Quality Test
Tue, 13 Jun 2006, 15:28:00 GMT — Edited by Christopher L. Simmons
LONDON, UK - June 13 (SEND2PRESS NEWSWIRE) -- Crescent Diagnostics Ltd. (Crescent), a privately held company developing a new test for bone health, today announced the completion of a GBP 550,000 (Euros 800,000) funding round. Seroba BioVentures (Seroba), a Dublin-based specialist life science venture capital firm led the round in conjunction with a number of private investors.

Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format
Thu, 01 Jun 2006, 05:12:00 GMT — Edited by Christopher L. Simmons
CORNWALL, UK and MALVERN, PA - June 1 (SEND2PRESS NEWSWIRE) -- Key Organics Ltd and Reaction Biology Corporation today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for 'rental' screening on RBC's DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright.

M2SYS Releases Bio-Plugin(TM) Parallel Server for Accelerated Processing of Large Scale Biometric Databases
Wed, 31 May 2006, 23:09:00 GMT — Edited by Christopher L. Simmons
ATLANTA, GA - May 31 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a biometric technology research and development company, announced today its release of Bio-Plugin(TM) Parallel Server, a highly scalable fingerprint recognition system that leverages distributed node balancing for fast, 1:N identification of large databases.

VIGILAIR Systems, Inc. Earns DHS 'Qualified Anti-Terrorism Technology' Designation
Tue, 16 May 2006, 21:44:00 GMT — Edited by Christopher Laird Simmons
WASHINGTON, DC - May 16 (SEND2PRESS NEWSWIRE) -- The U.S. Department of Homeland Security has designated the VIGILAIR(R) Biodefense System as a QATT (Qualified Anti-Terrorism Technology), in accordance with the SAFETY Act of 2002.

Southern Software, Inc. Deploys Integrated M2SYS Fingerprint Software within Jail Management Platform to Multiple Detention Centers for Positive Inmate Identification
Thu, 11 May 2006, 07:05:00 GMT — Edited by Christopher Laird Simmons
ATLANTA, GA - May 11 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a biometric technology research and development company, announced today that Southern Software, Inc. of North Carolina, a leading provider of municipal and public safety products, has successfully integrated the M2SYS Bio-Plugin(TM) fingerprint software technology into its Jail-Pak(TM) inmate management application and has deployed it to detention centers in Roanoke, VA, Benton County, AR, Hamblen County, TN, and Uvalde County, TX.

Education Management Systems, Inc. Integrates M2SYS Fingerprint Software into School Lunch Line POS and Financial Software
Wed, 12 Apr 2006, 17:59:00 GMT — Edited by Christopher Laird Simmons
ATLANTA, GA - Apr. 12 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a biometric technology research and development company, announced today it has finalized a long-term agreement with Education Management Systems, Inc. (EMS), a leading provider of school nutrition and financial software to the K-12 market. This agreement will benefit school customers by enabling EMS to integrate and distribute M2SYS' leading edge fingerprint software technology within the ISIS(TM) financial administration and Meals Plus+(TM) lunch line POS solutions. The integrated fingerprint software is now available to EMS' established customer base of more than 3,000 schools across the country.

Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies
Fri, 07 Apr 2006, 15:40:00 GMT — Edited by Christopher Laird Simmons
SAN MARINO, CA - Apr. 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.

Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, Calif. - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer
Tue, 04 Apr 2006, 18:08:00 GMT — Edited by Christopher Laird Simmons
SAN MARINO, CA - Apr. 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today the establishment of its main corporate headquarters in San Marino, California. The specialty pharmaceutical company has been granted Orphan Drug Status by the FDA for its lead product Rexin-G(TM), an innovative anti-cancer agent that seeks out and destroys metastatic disease. Rexin-G(TM) has been tested in a wide variety of cancer types, including pancreatic cancer, breast cancer, colon cancer, uterine cancer, laryngeal cancer, smooth muscle cancer (leiomyosarcoma) and skin cancer (malignant melanoma).

Dearman Systems, Inc. Integrates M2SYS Fingerprint Software to Safeguard Movement of Hazardous Materials in Petroleum and Chemical Distribution Industry
Thu, 16 Mar 2006, 17:14:00 GMT — Edited by Christopher Laird Simmons
ATLANTA, GA - Mar. 16 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced today it has finalized a long-term agreement with Dearman Systems, Inc., a leading provider of terminal automation software for the bulk petroleum and chemical distribution industry. This strategic agreement will benefit Homeland Security by enabling Dearman's customers to accurately identify persons transporting hazardous materials and cargo truckloads to many high security sites throughout the U.S.

Reaction Biology Corp. Awarded NIH R01 Screening Roadmap Grant for Microarray Screening Development
Mon, 13 Mar 2006, 21:06:00 GMT — Edited by Christopher Laird Simmons
MALVERN, PA - Mar. 13 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded an R01 grant from the National Institutes of Health to accelerate development of its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery. The NIH grant is part of the Screening Roadmap, designed to produce innovative chemical tools for use in biological research and drug development. Out of 8 recipients of grants pursuant to the original RFA, Reaction Biology is the only private corporation to be so awarded.

The Active Network Selects Patent-Pending M2SYS Fingerprint Software for Rapid Integration into Application Solutions Portfolio
Tue, 28 Feb 2006, 02:30 EST — Edited by Christopher Laird Simmons
ATLANTA, GA - Feb. 28 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced today it has finalized a long-term agreement with The Active Network, Inc., the leading provider of application services technology and marketing access to community services organizations. This agreement will benefit university campus recreation programs, school districts, the higher education market, and parks and recreation organizations by enabling The Active Network to integrate and distribute M2SYS' leading edge fingerprint technology within many of its software applications to tighten security, reduce costs, create operational efficiencies, and improve reporting accuracy.

Emerald Systems Partners with M2SYS to Provide Customers with Integrated Fingerprint Software for Positive Inmate Identification
Thu, 16 Feb 2006, 12:12 EST — Edited by Christopher Laird Simmons
ATLANTA, GA - Feb. 16 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced it has finalized a long-term partnership agreement with Emerald Systems, a leading provider of web based high technology applications for the public safety industry, to integrate the M2SYS patent-pending fingerprint recognition solution called Bio-Plugin(TM) into the Emerald JADE II Inmate & Facility Management System. The technology is now available to Emerald's growing customer base of detention centers throughout the U.S.

Discus Dental Selects M2SYS Enterprise Fingerprint System
Thu, 8 Dec 2005, 06:19 EST — Edited by Christopher Simmons
ATLANTA, GA - Dec. 8 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced it has finalized a long-term partnership agreement with Discus Dental, Inc., the leading manufacturer and seller of dental products and services for the dental healthcare industry, to integrate and distribute the M2SYS patent-pending fingerprint recognition solution called Bio-Plugin(TM) within the Discus Dental Software practice management suite. The solution is now available to Discus Dental's expansive global customer base.

Linus Inc. Selects M2SYS Fingerprint System for Rapid Integration into Mission Critical Point of Sale Software Solutions
Wed, 26 Oct 2005, 03:30 EDT — Edited by Christopher Simmons
ATLANTA, GA - Oct. 26 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, today announced that it has executed a long-term partnership agreement with Linus, Inc. to integrate and support the sale of its patent-pending fingerprint recognition solution called Bio-Plugin(TM) and its M2-S(TM) fingerprint reader. The technology will be added to Linus' RCOMX solution suite which includes Point of Sale (POS) applications for fine-dining restaurants, quick-service restaurants, online ordering, and supermarkets.

CTS America Completes Integration of M2SYS Enterprise Fingerprint Software in Less than 24 Hours
Wed, 5 Oct 2005, 02:38 EDT — Edited by Christopher Simmons
ATLANTA, GA - Oct. 5 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, today announced it has finalized a long-term partnership agreement with Consolidated Technology Solutions (CTS America), a leader in commercial state-of-the-art, integrated public safety software, to integrate the M2SYS patent-pending fingerprint recognition solution called Bio-Plugin(TM) into CTS's SmartJAIL(TM) and SmartRMS(TM) solutions. The technology is now available to CTS America's growing customer base of public safety customers throughout the U.S.

Breakthrough in Medical Imaging May Be Only a Fingertip Away
Fri, 23 Sep 2005, 11:32 EDT — Edited by Christopher Simmons
COLUMBUS, OH - September 23 (SEND2PRESS NEWSWIRE) -- PHIS, Inc. announced today that two peer-reviewed international journals, Kybernetes and Functional Diagnostics, published articles that may signal the beginning of a new era in medical imaging. According to an accompanying commentary by A. J. Tchizhov, M.D., 'I am firmly convinced that most departments of functional diagnostics will widely use such methods of non-invasive diagnostics in the near future.'

Neurotechnology Entrepreneur to Keynote 2005 Neurotech Leaders Forum
Tue, 13 Sep 2005, 07:03 EDT — Edited by Christopher Simmons
SAN FRANCISCO, Calif. - September 13 (SEND2PRESS NEWSWIRE) -- Alan Levy, President and CEO of Northstar Neuroscience, Inc., will keynote the 2005 Neurotech Leaders Forum, to be held in San Francisco, CA October 20-21. Levy, founder of one of the most promising venture capital-backed neurotechnology firms, will address many of the issues involved with launching a neurotechnology startup. The fifth annual event, produced by Neurotech Reports, will be held at the Crowne Plaza San Francisco International Airport. The conference will cover a range of technologies and market segments in the neuro space, including neuromodulation, neural prostheses, neurodiagnostics, and neurostimulation.

iEmployee Rapidly Integrates M2SYS Biometric Fingerprint System into Workforce Management Software; Deploys to First Customers in Less Than One Week
Tue, 23 Aug 2005, 10:45 EDT — Edited by Christopher Simmons
ATLANTA, GA - August 23 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, today announced that total workforce management solution company iEmployee has integrated M2SYS' Bio-Plugin(TM) biometric fingerprint identification system into their web-based PC time clock solution. The strategic partnership signals the expanding acceptance and recognizable value of using a reliable method to capture employee time and attendance data that is more convenient and affordable than a wall mounted time clock or manual time sheet. The addition of iEmployee to M2SYS' rapidly growing list of software integrator partners also secures M2SYS' position as an industry leader in providing robust and rapid biometric system integration into enterprise-level ASP software.

New ReLuma Beautifully Blends Science and Technology to Rejuvenate Aging Skin
Tue, 9 Aug 2005, 11:16 EDT — Edited by Carly Zander
MIAMI, Fla. - August 9 (SEND2PRESS NEWSWIRE) -- According to Advanced Therapeutic Solutions, LLC (ATS), excitement is running skin deep when it comes to ReLuma. The next generation in bio-engineered skincare has arrived and ATS is banking on physician and consumer preference for safe, effective, non-irritating human growth factors to treat aging and photo-damaged skin.

Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery
Tue, 9 Aug 2005, 10:56 EDT — Edited by Christopher Simmons
MALVERN, PA - August 9 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery.

Leon County, FL Selects M2SYS Fingerprint Recognition System as Alternative to SDK; Completes Integration in Under One Week
Tue, 26 Jul 2005, 12:47 EDT — Edited by Christopher Simmons
ATLANTA, GA and TALLAHASSEE, FL - July 26 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced today that the Leon County Detention Center in Tallahassee, Florida has selected the M2SYS fingerprint recognition solution for use within its 1,200-bed facility. The biometric system is integrated into the county's correctional facility management software, which was developed in-house.

Clinical Trial For Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector
Fri, 15 Jul 2005, 12:03 EDT — Edited by Christopher Simmons
LOS ANGELES, Calif. - July 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, announced today that a Phase I clinical trial has opened at Mayo Clinic Cancer Center, Rochester, Minnesota to test the safety of Rexin-GTM, the first tumor-targeted gene therapy vector to gain Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The clinical protocol has passed the rigorous reviews of the FDA, the NIH/Recombinant Advisory Committee, and the Institutional Review Board of Mayo Clinic.

M2SYS Delivers Integrated Biometric Technology to Largest Detention Center in Southeast For Process Improvements and Tightened Security
Wed, 22 Jun 2005, 12:19 EST — Edited by Christopher Simmons
ATLANTA, GA - June 22 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a global leader in biometric technology research and development, announced today that the DeKalb County Sheriff's Office in Atlanta, GA has selected the M2SYS fingerprint recognition solution for use within its 3,636-bed detention center. The biometric system is integrated into DeKalb's correctional facility management software provided by Digital Solutions Inc. (DSI), an M2SYS strategic partner.

Reaction Biology Corporation Awarded NIH Kinase Grant
Tue, 21 Jun 2005, 10:21 EST — Edited by Christopher Simmons
MALVERN, PA - June 21 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions.

Digital Solutions Inc. Partners with M2SYS to Address Demand for Robust Biometrics System from Law Enforcement Customers
Wed, 15 Jun 2005, 02:34 EST — Edited by Christopher Simmons
ATLANTA, GA - June 15 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced it has finalized a long-term partnership agreement with Digital Solutions Inc. (DSI), a criminal justice and public safety automation industry leader, to integrate the M2SYS patent-pending fingerprint recognition solution called Bio-Plugin(TM) into DSI's Offender Management System(TM). The technology is now available to DSI's growing customer base of detention centers throughout the U.S., and has already been adopted by the DeKalb County Sheriff's Office detention center; the largest in the southeast, processing 80,000 to 100,000 inmates annually.

M2SYS and Medibase Healthcare Solutions Lead Joint Session About Emerging Trend of Fingerprint Recognition Technology in Healthcare Industry
Thu, 9 Jun 2005, 02:39 EST — Edited by Christopher Simmons
ATLANTA, GA - June 9 (SEND2PRESS NEWSWIRE) -- M2SYS Technology, an innovator in biometric technology research and development, announced it has finalized a long-term partnership agreement with The Medibase Group, Inc., a leading software solutions provider for the healthcare industry, to integrate and distribute the M2SYS patent-pending fingerprint recognition solution called Bio-Plugin(TM) under the Medibase product name BASEmetric(TM).

M2SYS Forms Strategic Partnership with CSI Software to Fulfill Surging Biometrics Demand in Fitness Industry
Tue, 19 Apr 2005, 11:05 EST — Edited by Christopher Simmons
ATLANTA, GA -- (SEND2PRESS NEWSWIRE) -- M2SYS Technology, a global leader in biometric technology research and development, today announced that it has executed a long-term partnership agreement with CSI Software to integrate and support the sale of its patent-pending fingerprint recognition solution called Bio-Plugin(TM) and its M2-S(TM) fingerprint reader. The technology will be added to CSI's Spectrum(TM) membership management software and made available to its growing customer base of fitness clubs throughout the U.S.

TBS Announces First Touchless, 3D Live-Scan Fingerprint System
Tue, 5 Apr 2005, 08:31 EST — Edited by Christopher Simmons
HERNDON, VA -- (SEND2PRESS NEWSWIRE) -- TBS North America, Inc. (TBS), a touchless biometric system provider for high quality enrollment and identification applications, announced today Surround Imaging(tm), the first fingerprint capture technology to reconstruct the 3-dimensional features of the human finger.

Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector
Tue, 5 Apr 2005, 06:00 EST — Edited by Christopher Simmons
LOS ANGELES, Calif. and NEW YORK, NY -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer.

By News Article Editor: Christopher L. Simmons
Syntec Wins Accelerator Excellence Award at Annual Raytheon Supplier Forum
ROCHESTER, NY - September 8, 2004 /Send2Press Newswire/ -- At the 2004 Raytheon Supplier Forum, Syntec Technologies of Pavilion, NY (www.syntectechnologies.com) was singled out for its contribution to the Paveway II program, which is critical to US efforts in Afghanistan and Iraq. Raytheon recognized Syntec with its Accelerator Excellence Award. It was the only award of its kind at the forum and one of only seven awards in total.

By News Article Editor: Christopher Laird Simmons
ProteomTech, Inc. Secures Phase II SBIR Grant, for VEGI Anti-angiogenesis Drug Development
EMERYVILLE, Calif. - August 24, 2004 /Send2Press Newswire/ -- ProteomTech, Inc. (www.proteomtech-inc.com), a privately held biotech start-up, announced today that the company has been awarded a $750,000 Phase II SBIR grant from the National Cancer Institute (NCI) to develop the new anti- angiogenesis (cancer) protein drug, VEGI - vascular endothelial growth inhibitor.

By News Article Editor: Carly Zander
Testing Proves UV Effective at Killing SARS Virus
NEW YORK, NY - Aug. 6, 2004 /Send2Press Newswire/ -- A new laboratory study has demonstrated that Ultra Violet (UV) light can effectively kill the Severe Acute Respiratory Syndrome (SARS) virus. FP Technologies (www.vigilairsystems.com), an engineering firm that uses UV radiation to sterilize air and surfaces, designed the SARS testing. Tests were performed at ZeptoMetrix, Inc., a leading bio-tech lab that currently holds several contracts with the Centers for Disease Control.

News Article Editor: Carly Zander
First American Gains Therapeutic Benefit From REXIN-G, The Leading Tumor-Targeted Gene Therapy Vector For Pancreatic Cancer
LOS ANGELES, Calif. - May 13, 2004 /Send2Press Newswire/ -- Epeius Biotechnologies Corporation, today announced that the first American with advanced pancreatic cancer has responded favorably to Rexin-G, the leading tumor- targeted injectable gene therapy vector for metastatic cancer.

News Article Editor: Christopher L. Simmons
Health Discovery Corporation Announces Participation in the SCIA Conference
Savannah, Ga, April 7, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY) today announced that David Cooper, M.D., Ph.D., President and Chief Medical Officer of Health Discovery Corporation, was one of the presenters at the Southern California Investment Association conference on Saturday April 3rd which was held in Orange County, CA. Dr. Cooper discussed the status of Health Discovery Corporation, a genomic/proteomic/biotechnology company focused on biomarker and pathway discovery for diagnostic markers and drug targets.

News Article Editor: Carly Zander
Health Discovery Corporation Announces Agreement with the University of Miami for Biomarker and Pathway Discovery in AIDS related Dementia
SAVANNAH, GA - March 23, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY) today announced the signing of an Agreement with The University of Miami to use Health Discovery Corporations proprietary and patent protected Fractal Genomics Modeling (FGM) techniques to identify new patterns of biomarkers in AIDS Related Dementia. It is hoped that this newly discovered information will allow physicians to better understand the pathogenesis of AIDS Related Dementia and will assist in the diagnosis and treatment of this devastating disease.

[Business & Technology News Editor: Carly Zander]
Dr. Herbert A. Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at M.D. Anderson Cancer Center accepts position as Chairman of the Scientific Advisory Board of Health Discovery Corporation
WACO, Texas - Jan. 27, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY), a systems biology oriented biomarker and pathway discovery company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic drug candidates from complex genomic, proteomic and clinical data sets, is honored that Dr. Herbert Fritsche of M.D. Anderson Cancer Center has accepted the position as Chairman of the Company's Scientific Advisory Board joining other distinguished members including Dr. Kary Mullis, recipient of the Nobel Prize for his invention of PCR.
> READ NEWS ARTICLE

[Business & Technology News Editor: Carly Zander]
Health Discovery Corporation Announces Agreement With M.D. Anderson Cancer Center for Biomarker and Pathway Discovery in Prostate Cancer
WACO, Texas - Jan. 26, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY) today announced the signing of its second Biomarker and Pathway Discovery Agreement with The University of Texas, M.D. Anderson Cancer Center in Houston Texas. Under the terms of the Agreement, The University of Texas, M.D. Anderson Cancer Center, has granted the Company a first option to obtain an exclusive worldwide royalty- bearing commercial license to commercialize any discovered prostate cancer biomarkers or pathways identified by the Company utilizing its proprietary and patent protected Fractal Genomics Modeling (FGM) techniques.
> READ NEWS ARTICLE

[Business & Technology News Editor: Carly Zander]
Health Discovery Corporation Releases Shareholder Letter
WACO, Texas - January 8, 2004 /Send2Press Newswire/ -- Health Discovery Corporation, Inc. (OTC BB: HDVY) today released a letter to the shareholders from Dr. Stephen D. Barnhill Chairman and Chief Executive officer of Health Discovery corporation.
> READ NEWS ARTICLE

[Business & Technology News Editor: Carly Zander]
Health Discovery Corporation Completes the Acquisition of Fractal Genomics
WACO, Texas - January 2, 2004 /Send2Press Newswire/ -- Health Discovery Corporation, Inc. (OTCBB: HDVY) today announced the completion of the acquisition of Fractal Genomics in San Francisco, California. Fractal Genomics was founded by Sandy Shaw, a former bioinformatics specialist at the University of California, San Francisco and former computer scientist and software engineer with over twenty years of experience at Bell Labs, Lockheed Electronics and the University of Hawaii. As part of the acquisition, Sandy Shaw has assumed the position of Vice-President-Fractal Technology with Health Discovery Corporation.
> READ NEWS ARTICLE

[Biotech News Editor: Christopher Simmons, Senior Editor]
Dr. Tin-Chuen Yeung Named To Health Discovery Corporation Scientific Advisory Board
WACO, Texas - Nov. 25, 2003 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY), a biotechnology company which is focused on biomarker and pathway discovery for diagnostic markers and drug targets today announced the appointment of Dr. Tin-Chuen Yeung to its Scientific Advisory Board.
> READ NEWS ARTICLE   > PDF

[Newswire Editor: Christopher Simmons, Senior News Editor]
Health Discovery Corporation, Inc. Announces the Appointment of Joe Fanelli to the Management Team as Director of Corporate Development
WACO, Texas - Nov. 14, 2003 /Send2Press Newswire/ -- Health Discovery Corporation, Inc. (OTC BB: HDVY), today announced the appointment of Joe Fanelli to the Company's Management Team. Mr. Fanelli will assume the position of Director of Corporate Development for the Company. In this role, Mr. Fanelli will work on strategic alliances, partnerships, acquisitions, and licensees for the Company's patent protected biomarker discoveries.
> READ NEWS ARTICLE   > PDF